Trastuzumab plus Chemotherapy in Gastric Cancer Overexpressing HER-2 and EGFR: A Case Report

Publisher： Karger

E-ISSN： 2296-5262|34|1-2|42-45

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.1-2, 2011-01, pp. : 42-45

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Positive Response to Trastuzumab in a Case of HER2-Overexpressing Metastatic Gastric Cancer that Presented as Severe Thrombocytopenia

By  

Oncology Research and Treatment, Vol. 34, Iss. 11, 2011-10 ,pp. : 621-624

Karger

Access to resources Recommend Favorite

Combination of Trastuzumab and Triple FLOT Chemotherapy (5-Fluorouracil/Leucovorin, Oxaliplatin, and Docetaxel) in Patients with HER2-Positive Metastatic Gastric Cancer: Report of 3 Cases

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 505-508

Karger

Access to resources Recommend Favorite

A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer

By  

Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. : 38-45

Karger

Access to resources Recommend Favorite

Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 582-586

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Trastuzumab Every 3 Weeks Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive Recurrent Breast Cancer: Findings from a Case Series

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 558-564

Karger

Access to resources Recommend Favorite